Q-omics provides the consensus-scored H2AC19 profile across patient tissues and cancer cell-line models. H2AC19 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, H2AC19 is differentially expressed in 8, with the highest sampling consensus in STAD. Additionally, H2AC19 RNA expression shows 12,630 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, STAD, and LSCC as cancer lineages where H2AC19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2AC19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2AC19 survival associations across molecular data types. H2AC19 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2AC19 RNA expression–survival associations across cancer types. High H2AC19 expression shows unfavorable associations in UCEC, HNSC, SARC, UVM, THYM and ACC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify UCEC as the clearest survival context for H2AC19 RNA expression.
This table summarizes H2AC19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for H2AC19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2AC19 shows higher tumor expression in STAD, BRCA, LUAD, LUSC, KIRC and PRAD. The STAD box plot shows higher H2AC19 RNA expression in tumor versus normal tissue (log2 FC = +0.283, t-test p = .014).
This table shows molecular features associated with H2AC19 in patient tissues and cancer cell lines. In patient samples, H2AC19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, H2AC19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma.
